Company / Depreciation & Amortization
Supernus Pharmaceuticals, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$91.6M
FY2025
5-year range
$32.6M / $91.6M
FY2021-FY2025
Trend
+13.9%
vs FY2024
Sector context
#20 of 168
Health Care
What the data says
Supernus Pharmaceuticals, Inc.'s depreciation & amortization of $92M is higher than 88% of companies in the Health Care sector (FY2025). Depreciation & Amortization returned to growth in FY2025 after 2 years of decline, reaching $92M.
Based on SEC 10-K filings.
$92M in FY2025 with a 5-year CAGR of +38.2%. Top quartile in the Health Care sector.
Increased from $85M to $92M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +2.3%
- 5-Year CAGR
- +38.2%
- 10-Year CAGR
- -
Sector benchmark
-57.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +38.2%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 13.9% year-over-year.
- Ranks #20 out of 168 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $91.6M | +13.9% |
| FY2024 | $80.4M | -5.2% |
| FY2023 | $84.9M | -0.8% |
| FY2022 | $85.5M | +162.4% |
| FY2021 | $32.6M | +79.7% |
| FY2020 | $18.1M | +172.4% |
| FY2019 | $6.7M | +177.6% |
| FY2018 | $2.4M | +160.5% |
| FY2017 | $921.0K | -0.8% |
| FY2016 | $928.0K | +0.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026